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ABSTRACT
BACKGROUND: Multi drug resistant tuberculosis (MDR TB) is an emerging challenge for TB
control programs globally. According to the National DRS result in 2005, 1.6% of new cases and
11.8 % of previously treated cases wereMDRTB. According to WHO report on the prevalence of
MDR-TB in 2012,Ethiopia stands 15th out of the 27 high priority countries in the world and 3rd
in Africa following South Africa and Nigeria.
OBJECTIVES: The aim of this study was to assess the prevalence of MDR-TB and associated
risk factors in West Armachiho and Metema woredas of North Gondar.
METHODS: A cross-sectional study was conducted in West Armachiho and Metema
woredasbetweenFebruaryandJune 2014. All smear positive pulmonary tuberculosis patients
wereincluded in the study.Socio-demographic and risk factor data were collected using a semi-
structured questionnaire. Informed consent was obtained from study subjects and two morning
sputum samples were collected prior to starting anti-TB treatment for culture and drug
susceptibility testing. Culture was performed on Lowenstein Jenson Medium (LJ). Drug
susceptibility testing wasfirst performed for rifampicin using GeneXpertMTB/RIF.  For those
rifampicin resistant strains, DST was performed for both isoniazid and rifampicin to identify
MDR-TB using proportional method on LJ media. Finally, data wasentered, cleared and
analyzed using statistical Package SPSS version 20.  Tables and graphs were used to describe the
findings. Logistic regression was used to assess the association. P-value and 95% confidence
interval werealso used to assess the statistical significance.
RESULTS: Of 124 smear-positive pulmonary TB patients, 117 (94.4%) were susceptible to
Rifampicin, while 7(5.7%) were confirmed to be resistant to Rifampicin and Isoniazid. The
overall prevalence of MDR-TB was 5.7%(2.3% among new cases and 13.9% among previously
treated cases).History of previous treatment(OR=7, P=0.025) wassignificantly associated risk
factor for MDR-TB.
CONCLUSION AND RECOMENDATION:The overall prevalence of MDR-TB among new
and previously treated cases (5.7%) was considerably high. History of previous treatment was
risk factor for MDR-TB. Therefore, efforts to reduce the burden of MDR-TB such as early case
detection and treatment of MDR-TB, strengthening TB infection control activities and proper
implementation of DOTS should be made in the study area.
Key Words: Tuberculosis, MDR-TB, Risk Factors
11. INTRODUCTION
1.1Background
Tuberculosis is a major public health problem throughout the world. About a third of the
world’spopulation is estimated to be infected with tubercle bacilli and hence at risk of
developing active disease. According to the WHO Global TB Report 2012, there were an
estimated 8.7 million incident cases and 12 million prevalent cases of TB globally, about 26% of
the incident TB casesoccurred in Africa in 2011 (1).
Twenty twoHigh Burden Countries (HBCs) have been given highest priority at the global level
since 2000 which accounted for 82% of all estimated cases worldwide. Ethiopia is one of the 22
HBCs. According to the national population based TB prevalence survey conducted in 2010/11
the prevalence of smear positive TB among adults and all age groups was found to be 108 and 63
per 100,000 populations, respectively (2).WHO global TB report in 2012 estimated the
prevalence of all forms of TB was 200,000 (237 per 100,000 populations). Among these 15,000
deaths (18 per 100,000 populations) was due to tuberculosis (1-2).
Multidrug-resistant (MDR)tuberculosis (TB) caused by Mycobacterium tuberculosis strains
resistant to at least isoniazid and rifampin has emerged as a global epidemic resulting largely
from deficiencies in TB case management and program management (3). Approximately
425,000 MDR-TB cases occur annually worldwide, representing nearly 5% of the world’s annual
TB burden (4). Patients with MDR-TB require a much longer treatment period, usually 24
months, compared with the 6–8 months required for drug-susceptible TB (5). Additionally,
treatment requires the use of “second- line” drugs, which are more toxic and prohibitively more
expensive, with MDR-TB drug costs alone that are, on average, 100 to 300-fold higher than
those associated with drug-susceptible TB.Furthermore, patients with MDR-TB have lower cure
rates and higher mortality than do patients with drug-susceptible TB (5). In well-performing
MDR-TB programs in settings with a low HIV infection prevalence, treatment success is
generally 70%–80%; by comparison, treatment success for drug-susceptible TB in well-
performing TB programs can exceed 90% (6).
Resistance to the second line drugs also arise then the disease becomes virtually untreatable.
Extensively drug resistant-tuberculosis (XDR-TB) has been reported in all regions of the
2world (7). XDR-TB is defined as resistance to at least rifampicin, isoniazid, any of the second
line injectable drugs (capreomycin, kanamycin or amikacin) and any of the fluoroquinolones (8).
Control of drug resistant tuberculosis requires a strong health infrastructure to ensure the
delivery of effective therapy coupled with surveillance and monitoring activities to enable timely
intervention to limit transmission and spread of the disease(9).
Drug-resistant TB can be primary or secondary(acquired). Primary resistance is caused by
person-to-person transmission of drug-resistant organisms. Secondary resistance is drug
resistance in a patient who has received at least one month of anti TB treatment. Prior exposure
to anti-TB drugs is a well-established risk factor for drug resistance. In previously treated
patients, the probability of any resistance was over 4-fold higher, and of MDR-TB over 10-fold
higher, than for untreated patients. Among countries with a high burden of TB, previously
treated cases ranged from 4.4% to 26.9% of all patients registered in directly observed treatment
program. In the two largest high-TB burden countries (China and India) re-treatment cases
accounted for up to 20% of sputum smear-positive cases (10).
Drug-resistant TB is a man-made problem, largely being the consequence of human error as a
result of individual or combination of factors related to management of drug supply, patient
management, prescription of chemotherapy, patient adherence, poor infection control practice,
irrational drug use and generally poor Directly Observed Treatment (DOTS) implementation
practice has been identified as a major contributing factor for the spread of DR-TB (Drug
Resistance Tuberculosis). But spontaneous mutation of bacteria has also an effect for the
progression to DR-TB. Drug resistance tuberculosis, like drug susceptible TB, is transmitted
through inhalation of infected droplet nuclei (11).
1.2 Statement of the problem
1.2.1Global Burden of MDR-TB
Tuberculosis (TB) remains a major global health problem. In 2012, WHO estimates 8.6 million
people developed TB and 1.3 million died from the disease (including 940,000 among HIV-
positive and 320 000 deaths among HIV-negative people). Regarding MDR, in its estimation
there were 3·7% MDR (range 2·1–5·2%) of new cases and 20% MDR (range 13–26%) of
previously treated cases. The incidence of MDR-TB estimated to be 450,000 and the overall
3proportion of deaths from MDR-TB is 5.7% of the number of TB deaths which is unacceptably
large given that most are preventable. In eastern Europe  and  central  Asia, 9–32% of new
patients  and more   than   50%  of  previously  treated patients   have MDR tuberculosis (12).
The estimated proportion of MDR-TB for all countries was then applied to estimated new
(incident) TB cases.(13), it is estimated that 489 139 cases emerged in 2006, and that the global
proportion of resistance among all cases is 4.8% China, India and the Russian Federation are
estimated to carry the highest number of MDR-TB cases. China and India carry approximately
50% of the global burden, and the Russian Federation 7 % (14).
The high rates of MDR-TB were observed in the 2 most populous Chinese and Indian provinces.
In Henan Province, the most populous province in China, 11% of new cases had MDR-TB. In
Tamil Nadu, India, 3.4% of new cases had MDR-TB, the prevalence of isoniazid resistance was
15%, and rifampicin resistance was found in 4.4 % (15).
1.2.1. Burden of MDR-TB in Africa
According to WHO estimation nearly 60,000 MDR-TB cases occur annually in the Sub-Saharan
Africa region (14% of the global burden) (16). South Africa, with a nearly 20% HIV infection
prevalence among persons 15–49 years of age, has 11,000 MDR-TB cases annually (2.4% of the
global MDR-TB burden). Of these 1.8% was new TB cases. MDR-TB is more challenging and
much more expensive to treat than drug sensitive tuberculosis. Eight other countries have an
estimated annual MDR-TB incidence of 11,000 cases, including Cote d’Ivoire, Democratic
Republic of Congo, Kenya, Malawi, Mozambique, Tanzania, Zambia, and Zimbabwe (17).
According to the WHO/IUATLD survey, countries such as Mozambique, Cote D’Ivoire,
Cameroon, Argentina, the Dominican Republic, and Mexico are a concern because the
prevalence of MDR-TB in new cases is 13%. The full magnitude of the problem is still unknown
in a number of countries with high TB incidence, such as Democratic Republic of the Congo,
Ethiopia, Nigeria, Indonesia, Bangladesh, and Pakistan (18).
The prevalence of MDR-TB among new patients increased from 0.2% to 0.8%, in Botswana,
relatively high treatment default rates, uncontrolled use of second- line drugs for MDR-TB and
4high prevalence of HIV infection among patients with TB overall (60%–83%), increases in
MDR-TB(19).
In Kenya, with the fourth highest TB burden in the region, data from a 2002 national anti-TB
drug–resistance survey indicating that 0.8% of new patients with TB without prior treatment  and
3.6% of previously treated patients with TB had MDR-TB. This equates to a conservative
estimate of nearly 2400 new patients with MDR-TB annually (20).
1.2.3. Burden of MDR-TB in Ethiopia
According to WHO 2012 report, Ethiopia stands 15th out of the 27 high priority countries in the
world and 3rd in Africa following South Africa and Nigeria with (1600 and 480) among new and
retreatment cases respectively wereMDR-TB cases (1).According to the drug resistance survey
conducted nationwide in 2005 (EHNRI/FMOH), the prevalence of MDR-TB was: 1.6% in newly
diagnosed TB and 11.8% among previously treated TB cases(21).The country’s burden of MDR-
TB in 2009 was estimated to be 1500(870-2600) and 420(230-740) among new and re-treatment
cases respectively. Despite being a huge global threat, access to treatment is very limited with
only 10% of the estimated MDR-TB cases among notified TB cases in 2009 in the high MDR-
TB countries and 11% globally were enrolled on treatment (21).
A study conducted in North West of Ethiopia to assess the level and risk factors for first- and
second-line drug resistance among tuberculosis (TB) patients shows an overall prevalence of
5.0% multidrug-resistant (MDR) from which 3.7 % were from new cases and 10.9% were from
previously treated cases (22).
In West Armachiho and Metema woredas, information regarding TB treatment interrupters,
relapses, and failure cases were not well documented. According to the national comprehensive
TB/HIV and TBL guideline these are criteria for suspicion of MDR-TB. Moreover, as to our
knowledge there are only limited data regarding MDR-TB in this particular study area.
Therefore, the present study aimed to fill these gaps.
52. LITERATURE REVIEW
2.1 Prevalence of MDR-TB
A Population based cross-sectional study conducted in Georgia shows isolates recovered from
195 (14.8%) of 1314 patients had MDR-TB; with the prevalence of 6.8% in newly diagnosed
cases and 27.4% in re-treatment cases. Previous anti-TB treatment and gender (being female)
were risk factors for MDR-TB(23).
A cross-sectional, descriptive study In India shows: from a total of 196 pulmonary TB patients
which were screened; MDR-TB was detected in 40 (20.4%) patients. The mean age of MDR-TB
patients was 33.25. Of these 40 patients, 29 (72.5%) had relapse, 3 (7.5 %) had treatment failure
and 8 patients (20%) were defaulters. Nine patients (22.5%) were female. Thirty six patients
showed resistance to rifampicin and isoniazid; 4 patients showed resistance to streptomycin (in
addition to rifampicin, isoniazid) (24).
Another study in India Showed thatof 218 cases, whose mean age of the patients was 27.8 and 59
(27%) were female, a prevalence of MDR-TB among new sputum positive pulmonary TB
patients was 1.1%.two cases of MDR-TB were detected. Both were male, HIV negative, aged 20
and 25 yrs. and the resistance rates (%) observed to each first-line drugs of isoniazid and
Rifampicin were 6.2, rifampicin 1.1, respectively (25).
A study from Korea showed that among 637 patients which were enrolled in the study;
Resistance to at least one first-line drug was identified in 11.7% of new cases and 41.6% of
previously treated cases. MDR-TB was detected in 3.9% of new cases and 27.2% of previously
treated cases. Factors associated with MDR-TB were found to be age less than 45 yrs. and
previous TB treatment. (26).
A Surveillance report in Gujarat state of India showed; Of 1571 patients enrolled, prevalence of
MDR-TB was found to be 2.4%, 37 isolates from new patients, 173 (11%) had any INH
resistance and. But from 1047 isolates from previously treated patients, 387 (37%) had any INH
resistance and MDR-TB was found in 182 (27).
A five year retrospective study in India to assess drug resistance profiles of Mycobacterium
tuberculosis isolates to first line anti-tuberculosis drugs shows a prevalence of MDR was 320
6(47.54%) out of 673 M. tuberculosis isolates tested for drug sensitivity against first line drugs
(28).
A study from Pakistan Karachi shows that, the prevalence of MDR-TB  was 5.0 %,( new 2.3%,
previously treated 17.9%); and female gender and prior history of incomplete treatment were
found to be associated risk factors for MDR-TB(29).
A study conducted in Pakistan showed that 76/672 (11.3%) culture positive strains were resistant
to one or more drugs. Primary MDR-TB was 1.8% (n=12) (30).
In a study carried out in South Africa showedof 119,218 notified TB cases, 2799 (2.3%) were
multi-drug resistant (MDR).The two worst affected districts in the state were uMzinyathi where
226 (4.1%) of 5522 notified TB cases were MDR, and of these 120 (53%) were extensively drug
resistant (XDR), and uMkhanyakude where 337 (4.8%) of 6991 notified TB cases were MDR,
but, of these only 4 or (1.2%) were XDR. The worst affected medical centre was COSH where
164 or 9.8% of notified TB cases were MDR and of these 99 (60%) were XDR (31).
A study conducted in Nigeria showed that, the overall prevalence of multi-drug resistant
Mycobacterium tuberculosis among TB patients was found to be 5.8%. MDR-TB was found  to
be significantly  associated  with  HIV  seropositive patients ( 32% ) compared  to  HIV-
seronegative  (2.2%) patients (32).
A survey on primary anti-tuberculosis drug resistance conducted on smear positive pulmonary
TB patients in Addis Ababa showed that, of173 patients enrolled, 21.4% were resistant to at least
one drug. Single drug resistance was observed to isoniazid in 13.3%, to rifampicin in 1.2%. The
prevalence of resistance to at least one drug was 15.7% and 23.7% among patients with and
without HIV co-infection. Only one patient (0.6%) had a multidrug resistant (MDR) strain.
However, the prevalence of resistance to more than one drug was 10.4% (33).
A retrospective study on the prevalence of MDR-TB among retreatment MTB cases  conducted
in St.Peter Hospital, Addis Ababa showed that, of the total 84 patients resistance to at least one
drug was observed in 53.6% and 26.2% of the isolates were multi drug resistant (MDR)(34).
Another study in National TB Reference Laboratory in Addis Ababa showed that,of 107 M.
tuberculosis isolates recovered and tested for drug susceptibility against first line anti-TB
7drugs,MDR-TB was observed in one of the 44 new cases (2.3%) and 45/63 previously treated
patients (71.4%)(35).
2.2 Risk Factors of MDR-TB
A research conducted in Honk Kong, China showed that from 156MDR-TB patients,the risk
factors for acquiring the diseases were non-permanent residents, frequent travel and younger age
(36).
Risk factors for resistance can be those facilitating the selection of resistance in the community
and the specific conditions that appear to increase some patients' vulnerability to resistance. The
epidemiological situations varies greatly across countries, principally due to poor treatment
practices and poor implementations of control programme in the past and even today, to a lesser
degree and recent data have suggested that national TB programme that use existing drugs
efficiently can postpone and even reverse the MDR-TB epidemic. Factors’ leading to the MDR-
TB epidemic includes treatment failures with first-line rifampicin containing regimens, contacts
of MDR-TB cases and patients previously treated for TB causesthe highest rates of resistance
(37).
In A study conducted to detect risk factors for multidrug resistance in patients with pulmonary
tuberculosis in four European Union countries: France, Germany, Italy, and Spain done between
1997 and 2000. A total of 138 cases and 276 controls were studied. Considering the four
countries as a whole, the statistically significant risk factors were intravenous drug use; asylum-
seeker; living in a nursing home; previous tuberculosis with pulmonary location; prison; known
tuberculosis contacts; immunosuppression other than HIV/AIDS; current tuberculosis with
pulmonary location; and health-care worker (38).
A study conducted in Spain to identify factors associated with multidrug resistance. Patients with
positive culture for M. tuberculosis and with available drug-susceptibility tests were included.
Age, gender, country  of  origin, homelessness, alcohol consumption, intravenous drug use,
contact with a tuberculosis  patient, sputum  smear, previous tuberculosis treatment, HIV
infection, history of imprisonment, diabetes  mellitus and  chronic  obstructive pulmonary
disease were assessed. Thirty patients with MDR-TB and 666 patients with non-MDR-TB were
8included from the years 1997 to 2006. The factors associated with MDR- TB in multivariate
analysis were previous tuberculosis treatment, age group 45–64 years and alcohol abuse (39).
Indian study in a tertiary Hospital to assess Risk Factors for MDR and XDR-TB such as HIV
infection (tested in 134/203 (66%) cases), socioeconomic status, gender, age category, cigarette
use, alcohol use, site of TB disease, diabetes, residence outside of the state (referral patients),
cavitations on CXR, number of different previous treatment regimens, previous use of injectable
agents and fluoroquinolones and adequacy of initial treatment (defined as whether or not the
initial treatment regimen followed the regimen outlined by the national treatment program for
new smear positive TB patients were assessed. Previous treatment with an injectable and
fluoroquinolones was strongly associated with MDR (40).
A Population-based study on new and previously treated patients with TB collected within an
international drug resistance surveillance network. Of 9615 patients, which were enrolled 8222
(85.5%) were new cases of TB and 1393 (14.5%) were previously treated cases. Compared with
new cases, previously treated cases were significantly more likely to have resistance to two,
primary anti TB drugs. A linear increase in the likelihood of having MDR-TBwas observed as
the total time (measured in months) of prior anti-tuberculosis treatment increased (P < 0.001). In
multivariate analysis, prior TB treatment for 6–11 months (P < 0.001) and ≥12 months (P <
0.001), but HIV positivity, was not associated with MDR-TB (41).
A study conducted in Namibia showed, of the enrolled 117 MDR-TB cases and 251 TB controls,
among cases, 97% (113/117) had been treated for TB before the current episode compared with
46% (115/251) of controls. Cases were significantly more likely to have been previously
hospitalized and to have had a household member with MDR-TB. These associations remained
significant when separately controlled for being currently hospitalized or HIV-infection (42).
A retrospective study conducted in Nigeria indicates that out of the 88 patients who had drug-
susceptibility test result; there were 50 males and 38 females. The multi-drug resistant TB
(MDR-TB) rate was 76.4%. The only significant factor for the development of drug resistance
and MDR was the history of previous anti TB treatment (P<0.01). Other factors such as age and
gender were not significantly associated with drug resistance TB (43).
9A cross-sectional survey conducted in Swaziland shows MDR strain was isolated in 27 new
cases, resulting in MDRTB prevalence of 7.7%. Past TB treatment, being female, HIV infection,
and age 28–40 years were significantly associated with MDR TB. Past TB treatment and HIV-
infected patients were four times and two times more likely to be infected with an MDR TB,
respectively. The youngest age group was close to being significantly associated with MDR TB
regardless of HIV status and history of previous treatment (44).
A study focused on determinants of MDR-TB in Bangladesh shows younger age and, peri-urban
localities were associated with MDR-TB. History of contact and tuberculosis in the past were
four and eight times, a risk for MDR-TB, respectively, Regularity and always observation of
treatment, sputum conversion negatively associated with multi-drug-resistant tuberculosis.
Gender and socio-economic status did not show any influence (45).
A cross sectional study conducted in Jimma University specialized hospital, southwest
Ethiopiaamong new cases of smear positive TB patients to determine the pattern of resistance to
first-line drugs and risk factors. Multidrug-resistance TB (MDR-TB) was observed intwo
patients (1.5%). No statistically significant difference in the proportion of resistance by sex, age,
HIV status and history of beingimprisoned was observed (46).
A case control study conducted at St. Peter Hospital and five health centers in Addis Ababa
showed that, of the total 134 cases and an equal numberof controls which were enrolled in the
study, being male and history of previous treatment were risk factors for MDR-TB development.
But HIVinfection was not significantly associated with the occurrence of MDR-TB (47).
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3. SIGNIFICANCE OF THE STUDY
Tuberculosis case that has not been treated previously can harbor and expel bacilli resistant to
one or more anti-tuberculosis drugs (primary resistance); and patients who received
chemotherapy previously may present acquired drug resistance. Thus prevalence of Multi-drug
resistance is useful information on the implementation ofstandard chemotherapy regimens
designed and recommended by WHO for tuberculosis patients who have or have not been treated
previously.
Moreover, drug resistance rate can also serve as a useful parameter in the evaluation of quality of
current and past chemotherapy programme (DOTS). Therefore, understanding the drug
susceptibility patterns of Mycobacteriumtuberculosisis very crucial to treat patients, to decide
health priorities, to allocate resources, to monitor the emergency of resistance for planning
effective use of anti-TB drugs, to generate knowledge for health workers working in the study
area as well as will serve as a preliminary information for health programmers to give special
attention anddesign a package in the national TB control programme that addresses such areas
where hundred to two hundred thousands of people are employed in huge farms for the
production of crops.
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4. OBJECTIVES
4.1 General Objective
-To assess the prevalence and associated risk factors of MDR-TB among smear positiveTB
patientsin West Armachiho and Metema woredas of North Gondar.
4.2 Specific Objectives
- To determine the prevalence of MDR-TB in West Armachiho and Metema Woredas.
- To determine the prevalence of rifampicin resistant non-MDR-TB in West Armachiho and
Metema Woredas.
- To assess risk factors associated with MDR-TB in West Armachiho and Metema
Woredas.
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5. MATERIALSANDMETHODS
5.1 Study area
The study was conducted in West Armachiho and Metema woredas, in North Gondar Zone of
Amhara Region, North-west Ethiopia. West Armachiho woreda located about 210 kilometers far
from Gondar, 390 Kilometers from the Regional Capital, Bahir Dar and 955 kilometers away
from Addis Ababa, capital city of Ethiopia.Metema woreda is located about 180 kilometers far
from Gondar, 360 Kilometers from the Regional Capital, Bahir Dar and 925 kilometers away
from Addis Ababa in the North-west direction.The climatic condition of the woredas is mainly
hot, and average annual temperature is estimated to be between 320C- 440C. The mean annual
rainfall is about 1,521 mm. The Woredasare well known for Huge Agricultural Farms.
Administratively,West-Armachiho Woreda is divided into 14 kebeles. According to the 2005
Ethiopian fiscal year (2012/13) report of North Gondar Health Department the population of the
Woreda estimated to be 38,726.Every year up to 250,000 migrants comes to the woreda to be
employed in the farms. The Woreda has three Health Centers 2 of them (Abderafi and
Abirihajira Hcs) provides TB diagnosis and treatment and the other Gabla Hc provides only
treatment. Abderafi and Abirihajira Health Centers are the only well-established referral Health
Facilities in the woreda, together they provides Health care service to more than 22,000 peoples.
Regarding Metema, The woreda is divided into 22 kebeles.According to the 2005 Ethiopian
fiscal year (2012/13) report of North Gondar Health Department the population of the woreda
estimated to be 142,569.The woreda has 6 Health Centers(Metema, Gendewuha, Shinfa, Kokit,
Mesha, Meka) and Metema District hospitaland all of them provides TB diagnosis and treatment
and together they provides Health care service to more than 450,000 peoples. And every year up
to 500,000 migrants comes to the woredas to be employed in the farms.The woredas have public
services like mobile telecommunication, postal services, and chlorinated water supply system,
a12 hour’s generator power in West Armachiho and 24 hrs Power in Metema.
5.2 Study design and period
A cross-sectionalstudy was conducted among confirmed smear positive tuberculosis patients
who visited 9 health facilities in the woredas fromFebruaryto June 2014.
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5.3 Population
5.3.1 Source population
The source population was all patients who had a compliant of tuberculosis sign and symptoms
such as cough greater than two weeks, night sweating, weight loss more than 3 kilogram in a
month and visited the health facilities during the study period.
5.3.2 Study population
All confirmed smear positive tuberculosis patients who were diagnosed in Abderafi, Abirihajira,
Metema, Gendewuha health centers and Metema hospital, during the study period.
5.4 Sample size and sampling technique
The sample size for the study was determined by the following formula:
n= Z2 pq
d2
Where, n is the minimum sample size required;
Z= Is the Z score corresponding to  error of 5% (i.e., 1.96); or critical value at 95% certainty
(1.96)
P= 5%, the prevalence of Multi Drug Resistance TB =5%)(24).
q=1-p
d= marginal error between the sample and the population (0.05). Accordingly, the calculated
minimum sample size was 73. However, 124 study subjects were included in thestudy.
5.5 Sampling procedures
All consecutive smear positive TB patients diagnosed at the study sites during the study period
were included in the study.
5.6 Inclusion criteria
All smear-positive pulmonary TB patientswere included in the study.
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5.7 Exclusion criteria
- Smear positive TB cases who took treatment >1 month.
5.8Study variables
5.8.1 Dependent variable; MDR-TB
5.8.2 Independent variables;
Age, sex, residence, occupation, Income,educational status, HIV, smoking, TB contact history,
diabetes, fasting, history of prison, BCG vaccination status, are some of the in-
dependentvariables.
5.9 Data and sample collection
Data of socio-demographic and clinical variables from TB patients werecollected after careful
examination of patient history for new and previous anti-tuberculosis treatment. A structured
questionnaire was used to classify patients as ‘new’ and‘ previously treated’ TB cases and
laboratory diagnosis of TB based on national guidelines for microscopic examination of TBwas
performed :Three direct smears were prepared from three sputum specimens and stained using
Ziehl-Neelsen and Florescent Microscopy techniques for microscopic examination of AFB. Once
diagnosed, and confirmed of being smear positive tuberculosis patients, informed consent was
obtained from study subjects and two morning sputum sample from 5 to 10ml was collected
using standard sputum cup prior to starting anti-tuberculosis treatment. After collection sputum
specimens were re-cupped tightly to prevent leakage of AFB and stored at -20 0c refrigerator till
transported to University of Gondar Hospital and Bahir dar Regional Health Research
LaboratoryCenter. For transporting specimens standard triple package transportation carrier was
used.
Once the specimen reached University of Gondar Hospital, one sputum sample was used for
detection of Mycobacterium tuberculosis complex and resistance to rifampicin using GeneXpert
MTB/RIF- (fully-automated diagnostic molecular test, which simultaneously detects TB and
rifampicin drug resistance and provides accurate results within two hours) and the other sputum
sample was transported to Bahir dar Regional Laboratory Center for culture and drug
susceptibility testing for INH and RIF using Lowenstein Jenson media when the strain detected
as resistant to RIF by Gene5.9.1 Sputum decontamination, isolation and identification
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Smear positive sputum samples werere-confirmed using Gene X-pert and decontamination and
further homogenization was done according to Petroff’s method, with equal volume of sodium
hydroxide 4%, and centrifuged at 3000RPM for 20 minutes. Then the sediment was neutralized
and washed. Sputum specimen inoculated onto LJ slant (prepared as per the dry powder
manufacturer instruction).Incubated at 37oC and examined weekly. The result considered
negative if no growth was observed after 8 weeks. All mycobacterium isolates were identified
using standard biochemical methods and the presence of M. tuberculosiswas confirmed by
colonial morphology,positive niacin production and nitrate reduction tests.
5.9.2 Drug susceptibility testing (DST)
Sputum samples from all smear positive pulmonary tuberculosis cases were tested for drug
susceptibility to rifampicin using Gene x-pert machine and those patients who were resistant to
rifampicin tested for INH and RIFsusceptibility by solid culture method using LJ. Colonies of
isolated MTB from positive cultures were prepared by scraping from LJ slant into 3 ml of sterile
phosphate buffer saline (PBS) in sterile conical tube containing 4 glass beads. The tubes were
vortexed vigorously for several minutes in order to break up the clumps. Then the larger particles
were allowed to settle and the sediment was adjusted to a McFarland standard of 0.5. DST was
performed against first line drugs(INH and RIF) using the indirect proportional method on LJ
medium following standard procedures. Briefly, predetermined concentrations of drugs were
incorporated into LJ medium before solidification. The slant was subsequently inoculated with
the standardized prepared inoculum. Drugs at a concentration of INH 0.2mg/ml and RMP
40mg/ml wasused. The proportion method calculates the proportion of resistant bacilli present in
a strain. Two appropriate dilution of the bacilli, 10-2 and 10-4dilutions (undiluted = 106to 108
CFU/ml), were inoculated on drug-containing and drug-free media, in order to obtain countable
colonies on both media. The ratio of number of colonies observed on the drug-containing media
to drug-free medium indicates proportion of resistant bacilli present in the strain.
Below a proportion (critical proportion = 1%), the strain wasclassified as sensitive; otherwise
classified as resistant. HIV test results of study subjects were collected from TB unit register at
TB clinic of respective health facilities.
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5.10 Quality control of laboratory methods
The reliability of the study findings was guaranteed by implementing Quality control (QC)
measures throughout the whole process of the laboratory work. All materials, equipment and
procedures were adequately controlled.
5.10.1 Quality control of X-pert
Each test includes a sample processing control and probe check.
Sample Processing Control (SPC)-Ensures the sample was correctly processed. The SPC
contains non-infectious spores in the form of a dry spore cake that is included in each cartridge
to verify adequate processing of MTB. The SPC verifies that lysis of MTB has occurred if the
organisms were present and verifies that specimen processing was adequate. Additionally, this
control detects specimen- associated inhibition of the real-time PCR assay. The SPC should be
positive in a negative sample and can be negative or positive in a positive sample. The SPC
passes if it meets the validated acceptance criteria.  The test result will be “Invalid” if the SPC
was not detected in a negative test.
Probe Check Control (PCC)-Before the start of the PCR reaction, the GeneXpert
diagnosticsystem measures the fluorescence signal from the probes to monitor bead rehydration,
reaction-tube filling, probe integrity and dye stability. Probe Check passes if it meets the
assigned acceptance criteria.
5.10.2 Quality control of LJ Media
LJ culture media were tested for sterility by incubating for 48 hours at 37°c.Pre-analytical,
analytical and post-analytical stages of quality assurance that was incorporated in standard
operating procedures (SOPs) of the microbiology laboratory of Bahir dar Regional Health
Research Laboratorywas strictly followed. Quality control of drug susceptibility testingwas
performed by titrating the standard strainM. tuberculosis reference strain H37Rv (ATCC
27294)for each newly produced batch of drug susceptibility testingmedia.
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5.11 Data quality control
To assure data quality, data collectors was trained for two days how to use pre designed form and
5% of the sample was pre-tested in non-selected study facility at University of GondarHospital.
A constant monitoring process was framed as integral part of the data collection processes. The
data collectors were supervised daily. Supervisor handled problems, which arose, and received
and checked for completion of forms in order to clean up incorrect reporting and laboratory
examination. The supervisor in turn communicated with the principal investigator each day to go
through the completed forms and discuss problems. Therefore, there was a two-stage quality
control process throughout the data collection. Quantitative data was double entered to check
whether there was any inconsistency of data and avoided problems through the data entry
processes.
5.12 Data analysis
Quantitative and Qualitative data were entered, cleared and analyzed using the statistical package
SPSS version 20.0. After cleaning the data, descriptive statistics: percentages, means, medians,
standard deviations and ranges were used to describe the finding for each variable. Bivariate
logistic regression analysis was used to assess the association. P-value and 95% confidence
interval were used to assess for statically significance.Additionally, tables and graphs were used
for data presentation.
5.13 Ethical consideration
Before starting the data collection, ethical clearance was obtained from the School of Biomedical
and Laboratory sciences, University of Gondar. Written permission was obtained from North
Gondar Zone Health Department to West Armachiho and Metema Woreda Health Offices and
respective health centers. The objectives of the study were explained to the participants in a local
language (Amharic) and clarification was given. Written consent were obtained from each study
participant and those patients who were found to be confirmed MDR-TB cases were linked to
MDR-TB treatment initiation center at University of Gondar Hospital immediately for admission
and treatment follow up. Information obtained in each course of the study was kept confidential.
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5.14 Dissemination of results
The finding of this study will be officially distributed to all concerned bodies such as  Amhara
National Regional State Health Bureau,  North Gondar Health Department, West Armachiho and
Metema woredas Health office for interventions and Health service planning as well as to all
health facilities whom data were collected. In addition, the study will be presented to the health
staffs in health facility where the study is conducted. Moreover, the result will be presented at
University of Gondar staffs and students’ annual conference and other scientific conferences. A
manuscript will be prepared and submitted for publication in an appropriate journal.
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6. RESULTS
A total of 124 smear positive tuberculosis patients were included from five different heath
centers in West Armachiho and Metema Woredas. The health centers were Abderafi, Abirihajira,
Metema Yohannes, Gendewuha and Metema Hospital.
The proportion of smear positive tuberculosis cases in each health facilities were as follows:
Abderafi 49(39.5%), Metema Hospital,34(29.8%), Abirihajira 21 (12.9%), Metema yohannes16
(12.9%) and Gendewuha 4 (3.2%).Majority, 80 (64.5%) of the study participants were males, the
mean and median age of the study subjects were 32 and 29 years respectively. Their age ranges
from16–75 years. Nearly half, 46 (48.1%) were in the age range of 26–35 year, while 37 (29.8%)
were below 25 years old.
Of 124 study subjects, 66 (53.2%) were urban inhabitants and 40 (32.3%) were farmers. The
majority, 116 (93.5%) of the study subjects were Christians by religion while the rest 8 (6.5%)
were Muslims.  More than half, 64 (51.6%) were illiterate (Table 1).
Table 1: Socio-demographic characteristics of study subjects in West Armachiho and Metema
Woredas,NorthwestEthiopia February to June 2014.
Variable
Age group in year’s
Number (%)
<25 37(29.8%)
26-35 57(46%)
36-45 16(12.9%)
>46 14(11.3%)
Gender
Male 80 (64.5%)
Female 44 (35.5%)
Resident
Urban 66(53.2%)
Rural 58(46.2%)
Occupation:
Farmer 40(32.3%)
House wife 28(22.6%
Government employee 4(3.8%)
Merchant 16(12.9%)
Daily laborer 19(15.3%)
Driver 5(4%)
Student 8(6.5%)
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Income/ month:
< 500 birr 39 (31.5 %)
500 birr - 999 birr 55 (44.4%)
> 1000 birr 25(20.2%)
No means of income 5(4.0%)
Religion:
Christian 116(93.5%)
Muslim 8(6.5%)
Ethnicity:
Amhara 102(82.3%)
Tigre 22(17.7%)
Educational Status:
Illiterate 54(51.9%)
Primary School 31(29.8%)
Secondary School 16(15.4%)
Diploma 3(2.9%)
Marital Status:
Married 51(49%)
Un married 38(36.5%)
Widowed 5(4.8%)
Divorced 10(9.6%)
Prevalence of Multi- drug resistant tuberculosis (MDR-TB)
Sputum samples of the 124 smear positive tuberculosis patients were tested for multi drug
resistance tuberculosis by using Gene-Xpert MTB/RIF technique and conventional solid
culture, The overall prevalence of MDR-TB was 7(5.7%) and prevalence of MDR-TB
among new smear positive TB cases was2(2.3%) and among previously treated smear
positive TB cases 5(13.9%). Outcome of the last treatment of the 5 previously treated
smear positive Pulmonary TB cases which were confirmed MDR-TB, were 1 (20%) cured,
3(60%) were treatment failures and the other 1 (20%) was defaulter.
Of these confirmed MDR-TB subjects six were males and one was female(Figure1).Two of
the confirmed MDR cases were co-infected with HIV while, the other five were sero-
negative.The prevalence of HIV co-infected with MDR-TB was 28.6%.
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Figure 1:Gender distribution of Multi drug resistant tuberculosis
Among the five health facilities,MDR-TB cases were obtained from Abderafi health center
and Metema District Hospital. Three MDR-TB cases (one from new smear positive study
subjects and two from retreatment cases) were identified from Abderafi health center. The
other four MDR-TB cases (one from new smear positive study subjects and three from
retreatment cases) were identified from Metema hospital (Figure 2).
HC=Health Center
Figure 2:Prevalence of MDR-TB in Five Health Facilities of West Armachiho and Metema
Woredas
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Of 124 study subjects 70 study subjects were enrolled from West Armachiho woreda and
the remaining 54 subjects were from Metema woreda.The prevalence of MDR-TB in West
Armachiho woreda (4.3%)was slightly smaller than Metema woreda (7.4%) Figure3.
Sm+Ve=Smear Positive
Figure 3:Comparison of MDR-TB prevalence in West Armachiho and Metema woredas
Rifampicin resistant Non-MDR-TB
Sputum samples of 124 smear positive pulmonary TB cases were processed using GeneXpert
MTB/RIF for detection of Mycobacterium tuberculosis and identification of rifampicin resistant
strain. Of these only seven smear positive cases were found to be rifampicin resistant. Sputum
samples of rifampicin resistant cases were further diagnosed with solid culture (Lowenstein
Jenson) medium for growth of Mycobacterium tuberculosis and detection of isoniazid resistance
as well as confirmation of rifampicin resistant strain. The result showed rifampicin resistant non-
MDR-TB isolates were not observed from all rifampicin resistant isolates that were detected by
GeneXpert MTB/RIF for drug susceptibility testing. All seven rifampicin resistant isolates were
found to be MDR-TB cases.
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Risk Factors for MDR-TB in West Armachiho and Metema woredas
Of the 124 study subjects, 88 (71%) were found to be new smear positive tuberculosis cases
where as 36 (29.0%) were previously treated cases, and from those 36 previously treated study
subjects 24 (66.7%) were treated for pulmonary tuberculosis once, whereas 11(30.5%) were
treated twice at different time and place, the other 1 (2.8 %) where treated three times. Regarding
the outcome of the previous treatment of study subjects 25 (69.4%) of them were cured/treatment
completed, 6 (16.7%) were treatment failures, and 5 (13.9%) were defaulters.Of the 124 study
subjects, 28 (22.6%) were found to be co-infected with HIV and the rest 96 (71.4%) were HIV
negative. All study subjects did not have a history of taking anti-TB treatment from illegal drug
dealers rather they took from public health facilities.
Of 124 smear-positive pulmonary TB patients, 35 (28.2%) have had a history of smoking whereas
89 (71.8%) were non-smokers, and of those smokers, 9 of them found to be smoking while they
are taking anti-TB treatment. Eighty three (66.9%) of the study subjects have had a history of
frequent contact with chronic coughers before they were infected with Mycobacterium
tuberculosis whereas the other 41 (33.1%) were not. Regarding diabetic history of study subjects,
7 (5.6%) of them have had diabetics whereas the majority of them117 (94.4%) were non-diabetic.
The majority of study subjects, 106 (85.5%) were without a history of imprisonment but 18
(14.5%) were imprisoned and from those imprisoned 8 (44.4%) were on custody for less than one
month and the other 10 (55.6%) were on custody for more than one month. Vaccination status of
the study subjects for BCG showed, 96 (77.4%) were not vaccinated but the rest 28 (22.6%) were
vaccinated.
The relationship between individual exposure variables and MDR-TB status is shown in Table2.
Association between potential exposure variables and MDR-TB were analyzed. Socio-
demographic determinants such as age, sex.residence, occupation, income, religion, fasting,
ethnicity, educational status, marital status, and factors such as contact history, history of
imprisonment, number of rooms in the house, family number in the house hold, rooms for
sleeping, number of windows and use of substances like cigarette smoking and other clinical
characteristics such as, diabetes, history of previous anti-TB treatment, outcome of previous
treatment,BCG vaccination,HIV status, history of taking illegal anti-TB treatment, were assessed
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and all the variables that were considered important were entered to the binary logistic regression
models and analysis showed there were significant association between MDR-TB and history of
previous anti-TB treatment (OR:7, 95% CI=1.2-37.6, P=0.025). However, there were no
significant association between other variables and  MDR-TB. After adjustment for interactions
among the independent variables with the binary regression model; analysis also showed there
were no significant association between independent variables and prevalenceof MDR-TB
(P>0.05) with each factors other thanprevious treatment history.
Table 2: Factors associated with the prevalence of MDR-TB among Pulmonary TB cases, West
Armachiho and Metema woredas, Northwest Ethiopia,February to June 2014.
Variable Study
subjects: N
(%)
MDR-TB
N (%)
Crude OR P-Value
Total 124(100%) 7 (5.7%)
Age group in
year’s
<25 37 (29.8%) 1(14.3%) 2.77 (0.16, 47.56) 0.483
26-35 57 (46%) 4 (57.1) 1.02 (0.11,9.90) 0.987
36-45 16 (12.9%) 1 (14.3%) 1.15 (0.07,20.34) 0.922
>46 14 (11.3%) 1 (14.3%) 1
Gender
Male 80 (64.5%) 6 (85.7%) 3.49 (0.41, 29.9 4) 0.255
Female 44 (35.5%) 1(14.3%) 1
Resident
Rural 58 (46.2%) 4 (57.1%) 1.56 (0.33, 7.26) 0.574
Urban 66 (53.2%) 3 (42.9%) 1
Occupation:
Farmer 40(32.3%) 4(57.1%) 3.15 (0.67, 14.79) 0.146
Non Farmer 88(67.7% 3(42.9%) 1
Religion:
Christian 116(93.5%) 7(100.0%) 1.16 (0.06,22.17) 0.919
Muslim 8(6.5%) 0(0%) 1
Ethnicity:
Amhara 102(82.3%) 4 (57.1%) 1
Tigre 22(17.7%) 3 (42.9%) 3.87 (0.80,18.70) 0.092
Educational Status:
Illiterate 54(51.9%) 2(28.6%) 5.17(0.41, 65.68) 0.206
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Primary School 31(29.8%) 3(42.9%) 1.83(0.16,20.71) 0.624
Secondary School 16(15.4%) 1(14.3%) 2.67(0.14,49.76) 0.511
Diploma and
Above
3(2.9%) 1(14.3%) 1
Fasting
Yes 76(61.3%) 3(43%) 0.45(0.10, 2.12) 0.313
No 48(38.7%) 4(57%) 1
History of
Smoking
Yes 35(28.2%) 2(28.6%) 1.02(0.19, 5.51) 0.983
No 89(71.8%) 5(71.4%) 1
BCG vaccination
Yes 28(22.6%) 1(14.3%) 1
No 96(77.4%) 6(85.7%) 1.80 (0.21, 15.61) 0.593
History of
Previous
Treatment
Yes 36(29%) 5(71.4%) 6.94(1.28, 37.60) 0.025 *
No 88(71%) 2(28.6%) 1
HIV status
Yes 28(22.6%) 2(28.6%) 1.40(0.25, 7.64) 0.698
No 96(77.4%) 5 (71.4%) 1
History of Prison
Yes 18(14.5%) 1(14.3%) 0.98(0.11, 8.66) 0.986
No 106(85.5%) 6(85.7%) 1
History of Contact
to TB cases
Yes 83(66.9%) 7(100%) 8.14(0. 45,146. 06 0.155
No 41(33.1%) 0(0%) 1
N=number of subjects;OR=Odds Ratio
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7. DISCUSSION
The present study was mainly aimed at determining the Prevalence of MDR-TB and risk factors
for drug resistance tuberculosis among smear positive pulmonary cases in West Armachiho and
Metema woredas, Northwest Ethiopia. The overall prevalence of MDR-TB among new and
previously treated smear positive pulmonary tuberculosis cases were 5.7%. This finding is
comparable to the rates reported in Northwest Ethiopia 5% (22), Nigeria 5.8% (32), and Karachi
5% (29),  However, higher prevalence of MDR-TB were reported in Georgia 14.8% (23),India
20.4% (24),India 47.5%(28),Addis Ababa 43%(34),and Nigeria 76.4% (43).The higher level of
prevalence of MDR-TB in Georgia, India and Addis Ababa compared to the present study might
be due to the difference in the study subjects, As in the previous studies the majority of study
subjects included were MDR-TB suspects whom they were referred from different facilities for
confirmation of MDR-TB, drug susceptibility test and treatment due to failure of TB patients to
first line anti-tuberculosis treatment.On the contrary the present study showed a higher
prevalence compared to the findings in India1.1% (25),Gujarat2.4% (27),Pakistan1.8% (30),
uMzinyathiDistrict, KwaZulu-Natal state, South Africa2.3% (31),Nationwide anti-TB drug
resistance survey conducted in Ethiopia by EHNRI/ FMOH in 20052.0% (2,21),Addis
Ababa0.6% (33) and Jimma1.5% (46).the reason for the observed difference might be the
difference in the study periods as the previous studies were conducted in a relatively low
prevalence of MDR-TB era.
The prevalence of MDR-TB among new smear positive pulmonary TB cases in this study was
2.3% comparable to the studies conducted in Gujarat2.4% (27),Karachi, Pakistan2.3% (29), and
Addis Ababa2.3% (35).However, it is lower than from findings in Georgia, Eastern Europe 6.8%
(23), and Swaziland 7.7% (44); the lower prevalence in this study might be due to MDR
prevalence in the general populationis very high in those countries compared to Ethiopia.
However, this study reported a higher prevalence of MDR-TB from new cases (2.3%) compared
to the findings of the Nationwide anti-TB drug resistance survey in Ethiopia 1.6% (2,21),
India1.1% (25), and Jimma1.5% (46).The reason for the higher MDR-TB prevalence among new
cases in the present study might be large number of people to work in huge farms for the
production of crops in the study area share the same house or camp for sheltering and mostly
crowded and it also reflects the wider spread of MDR-TB in the area and the fact that sufficient
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control measures are not taken to prevent the development and the  transmission of drug-resistant
TB in study areas.
Of the 36 previously treated smear positive tuberculosis cases included in this study 5(13.9%)
were found to be MDR-TB, this finding is lower than other studies in Georgia27.4%
(23),India20.4% (24), Korea27.2% (26), Karachi17.9% (29) and in Addis Ababa71.4%(35).The
lower prevalence in the present study might be due to the difference in study subjects,as the
previous studies included only TB patients referred for culture and DSTfor confirmation of
MDR-TB and treatment. However the present study showed a higher prevalence compared to the
findings of two studies in Ethiopia: the Nationwide anti-TB drug resistance survey 11.8%(21)
and First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia 10.9%(22).The
higher prevalence of the present study compared to the previous two studies in Ethiopia might be
due to the fact that high proportion of previously treated in the study areas i.e. 29%of the smear
positive cases were found to be previously treated unlike the prevalence survey finding 8.6%
(21),and First-line and second-line anti-tuberculosis drug resistance in Northwest Ethiopia17.7%
(22).Moreover this finding may show poor implementation of DOTS in the study area; though,
all the five facilities are TB treatment health facilities, most of study subjects 59(47.6%) were
either farmers or daily labors and this study subjects spent their time working in huge farms
where there is no nearby clinic or temporary DOTS center in the camp that provides DOTS.
Implementation of poor quality of DOTs might have contributed to the emergence of TB
treatment failures, defaulters and relapses which leads to high prevalence of MDR-TB in
previously treated patients in the study areas.
MDR-TB among previously treated patients had higher prevalence than among new subjects,
this finding agrees with findings of other studies in Asian countries: Korea, 27.2% among
previously treated and 3.9% among new subjects (26), Karachi, 17.9%among previously treated
and 2.3% among new cases (29) , Georgia, 14.8% among previously treated and 2.3% among
new (23),and other studies from Ethiopia: Nationwide anti-TB drug resistance survey conducted
by EHNRI/ FMOH, 11.8% among previously treated and 1.6 % among new (21), First- and
second-line anti-tuberculosis drug resistance in Northwest Ethiopia, 10.9%among previously
treated and 3.7% among new cases (22).
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The prevalence of MDR-TB in the two districts is quite different compared to each other; from
70 smear positive pulmonary TB study subjects enrolled in West Armachiho woreda 3 of them
were found to be 4.3% (2.1% among new subjects and 9.1% among previously treated) which is
lower than the findings in Metema 7.4%,(5% among new subjects and 21.4% among previously
treated) the reason for the higher prevalence in Metema woreda might be due to unequal
recruitment of study subjects in both woredas and West Armachiho woreda contributes 70
subjects whereas Metema woreda only 54.
Of the 7 Rifampicin resistant strains identified by using X-pert MTB/RIF (GeneXpert diagnostic
system) none of them were isoniazidsensitive. This finding is different from other studies in
India1.1% (25), and Addis Ababa 1.2% (33). The reason might be due to the relatively low
number of rifampicin resistant strains identification in the present study.
In the present study association between potential exposure variables and MDR-TB were
analyzed using logistic regression model. History of previous treatment was the only
significantly associated risk factor with MDR-TB (OR:7, 95%CI=1.28-37.6,P=0.02).This finding
agrees with findings of other studies such as international drug resistance survey(41), Europe;
Georgia(23), four European Union countries: France, Germany, Italy, and Spain (38), Asian
countries: Korea(26),Karachi(29),and India(40),also with other African countries such as Nigeria
(43), and Swaziland (44).Moreover, this study agrees with other findings in Northwest
Ethiopia(22),and Addis Ababa(47), and in this study previously treated patients have had seven
times at risk of developing MDR-TB than new smear positive pulmonary cases.
In the current study, HIV status had no significant association with MDR-TB. This finding
agrees with the finding in other studies in Ethiopia: the nationwide anti-TB drug resistance
survey (21), First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia (22),
Addis Ababa (35), and Jimma (46), had come up in their respective finding that HIV status was
not the risk factor for the development and emergence of MDR-TB.However, other studies from
African countries Nigeria (32) and Swaziland (44) contradicted this finding and concluded HIV
was significantly associated with MDR-TB. The possible explanation for HIV infected study
subjects were not at risk for the development of MDR-TB than sero-negative patients in the
present study might be, being HIV positive might lead the study subject to be infected with
primary tuberculosis due to immunosuppression and TB is the major opportunistic disease that
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might occur throughout the life time of HIV positive subjects.Hence HIV didn’t specifically
leadMycobacterium tuberculosis strain to undergo spontaneous mutation so that it would
promote DR-TB.
The present finding shows no significant association of age with MDR-TB. This study is in
agreement with studies from four EuropeanUnion countries: France, Germany, Italy, and
Spain(38), India (40), Nigeria (43),and other parts of Ethiopia; Jimma (46), and Addis Ababa
(47). However, other studies in Honk Kong(36), Swaziland(44), and Bangladesh (45) reported
that younger age group was at risk for the emergence and development of MDR-TB. On the
contrary: study in Spain (39),showed that getting old was the risk factor for MDR-TB compared
to younger age group.In the present study Gender was also not significantly associated with
MDR-TB, unlike the findings of other studies in Georgia (23),Karachi(29),and Swaziland (44),
which reported being female was the risk for MDR-TB. However, similar findings compared
with the present study were reported in
Korea(26),Nigeria(32,43),India(40),Bangladesh(45),Jimma(46),and Addis Ababa(47).A report in
Hong Kong(36), showed non-permanent resident and frequent travel was significantly associated
with MDR-TB.However, this study did not show any significance difference. The reason for the
insignificant association of socio-economic characteristics such as age, sex, resident in this study
might be the small number of MDR-TB cases identified in this study.
30
8. STRENGTH
The use of a fully-automated diagnostic molecular test for diagnosing Rifampicin resistant
Mycobacterium tuberculosis complex (GeneXpert MTB/RIF) in this study could be considered
as the strength. Moreover, all the study subjects identified as MDR-TB was successfully linked
to the MDR-TB treatment initiation center of the University of Gondar teaching hospital.
9.LIMITATION
The present study could not be without limitations and the main limitation that occurred was the
small number of MDR-TB cases resulted difficulty in applications of statistical packages to
assess risk factors associated with MDR-TB. Only accessible facilities in terms of transportation
and facilities with relatively higher number of smear positive TB cases in West Armachiho and
Metema woredas were included in the study.
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10. CONCLUSION
On this particular study, a considerably high overall prevalence of MDR-TB among new and
previously treated cases 5.7%was founded. The prevalence of MDR TB among retreatment cases
was greater than the new cases 13.9% and 2.3%, respectively. History of previous anti TB
treatment were the only statistically significant risk factor for MDR TB. All seven rifampicin
resistant strains were also isoniazid resistant (rifampicin resistant non-MDR-TB cases were not
identified).
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11. RECOMMENDATION
Based on the study findings the following recommendations are forwarded.
 Establishment of seasonal DOTS centers and diagnostic laboratory facilities should be
considered, as there are huge farms and continues flow of people for work.
 Improved infection control measures need to be strengthened and implemented in the study
area and broadly in the North Gondar to reduce the risk of DR-TB transmission in the
community.
 Daily laboures who had been working in these woredas should be screened for tuburclosis
before they want back to home.
 Establishing MDR-TB initiation as well as diagnostic centers to cope up with considerably
high prevalence of MDR-TB patients in the study area.
 Regular monitoring mechanism of proper implementation of DOTS should be established
to increase treatment success rate thereby to reduce treatment failures, defaulters.
 Further studies should be conducted in the study areas with special focus on the
determinants for the considerably high prevalence of MDR-TB in the area.
 Provision of rapid diagnostic tools for the identification of drug resistance TB in the
referral health facilities, so as to increase case detection and identification of MDR-TB.
33
12. REFERENCES
1. WHO. Global tuberculosis report. Geneva, Switzerland: WHO, 2012.
2. FMOH Guidelines for Clinical and Programmatic Management of TB, TB/HIV and Leprosy
in Ethiopia.Addis Ababa, 2013.
3. World Health Organization: Global tuberculosis control: surveillance, planning, financing.
Geneva, Swizerland: WHO, 2006.
4. Corbett EL, Marston B, Churchyard GJ, De Cock KM: Tuberculosis in sub-Saharan Africa:
opportunities, challenges, and change in the era of antiretroviral treatment.
Lancet. 2006; 367(9514):926-37.
5. LawnSD, Wilkinson R: Extensively drug resistant tuberculosis. BMJ. 2006; 333 (7568):
559-60.
6. WrightA,Bai G,Barrera L,Boulahbal F,Martin-Casabona N,Gilpin C etal:Emergence
ofMycobacterium tuberculosis with extensive resistance to second-line drugs
worldwide,2000-2004.MMWRMorbMortalWklyRep. CDC; 2006;5(55):301-05.
7. Nathanson E, Lambregts-van Weezenbeek CS, Rich MJ, Gupta RJ, Bayona J, Blöndal K,
Caminero JA,etal: Multidrug-resistant Tuberculosis Management in Resource-limited
Settings.Emer Infect Dis. 2006; 12(9):1389-97.
8. Espinal MA, Dye C: Can DOTS Control multidrug-resistance tuberculosis? Lancet2005;
365(9466):1206-09.
9. Pablos-MendezA, Gowda DK, Frieden TR: Controlling multidrug-resistant tuberculosis and
access to expensive drugs: a rational framework.Bull World Health Organ2002,80(6):489-
95.
10. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva,
Switzerland: WHO,2006.
11. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva,
Switzerland: WHO,2009.
34
12. José A. Caminero:Guidelines for Clinical and Operational Management of Drug-Resistant
TuberculosisIUATLD Paris, France, 2013:20-21.
13. Yong Kim J, Shakow A, Mate K, Vanderwarker C, Gupta R, and Farmer P: Limited good
and limited vision: multidrug-resistant tuberculosis and global health policy.SocSci
Med. 2005; 61(4):847-59.
14. Cohn DL, Bustreo F, and Raviglione MC: Drug-resistant tuberculosis: review of the
worldwide situation and the WHO/IUATLD Global Surveillance Project. IUATLD. Clin
Infect Dis. 1997; 24 (Suppl 1):121-30.
15. WHO: Anti-tuberculosis drug resistance in the world: Report Number 3, Geneva,
Switzerland: WHO,2004.
16. World Health Organization: Anti-tuberculosis drug resistance in the world. Report no. 2:
Prevalence and trends Geneva, Switzerland: WHO,2000.
17. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, Williams BG,Dye
C: Global incidence of multidrug-resistant tuberculosis.J Infect Dis. 2006;194(4):479-85.
18. Aziz MA, Wright A. WHO/IUALTD Global Project on surveillance for anti-tuberculosis
drug resistance,Geneva, 2005: 15.
19. Republic of Botswana, Ministry of Health. Report of the evaluation of the National
Tuberculosis Programme, 2006:10-11.
20. Githui WA, Meme HK, Kutwa A, et al. Anti-tuberculosis drug resistance surveillance in
Kenya, 2002. Int J Tuberc Lung Dis.2006; 10(Suppl 1):186–87.
21. FMOH: World TB day Annual Bulletin, Addis Ababa, Ethiopia, 2012: 34.
22. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. First and second-line anti-tuberculosis
drug resistance in Northwest Ethiopia. Int J Tuberc Lung Dis. 2012;16(6):805-11.
23. N.Lomtadze,R.Aspindzelashvili,M.Janjgava, V.Mirtskhulava, A.Wright,HM,Blumberg, and
A.Salakaia. Prevalence and Risk Factors for Multidrug-Resistant Tuberculosis in Republic
of Georgia: Int J Tuberc Lung Dis. 2009; 13(1): 68–73.
35
24. Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, Singh U, Hanif M, Vashisht
RP:Prevalence of multidrug-resistant tuberculosis among category II pulmonary
tuberculosispatients. Indian J Med Res. 2011; 12(133):312-15.
25. Surendra K. Sharma, Gaurav Kaushik, BrajeshJha, Ninoo George, S.K. Arora, Deepak
Gupta, Urvashi Singh, Mahmud Hanif: Prevalence of multidrug-resistant tuberculosis
among newly diagnosed cases of sputum-positive pulmonary tuberculosis. Indian J Med
Res. 2011; 133(3): 308–11.
26. Choi JC, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, Lee NY, Park YK, Bai GH, and
Koh WJ: Drug resistance rates of Mycobacterium tuberculosis at a private referral center in
Korea. J Korean Med Sci. 2007; 22(4):677-81.
27. Ramachandran R, Nalini S, Chandrasekar V, etal. Surveillance of drug-resistant tuberculosis
in the state of Gujarat. Int J Tuberc Lung Dis. 2009; 13(9):1154-60.
28. Menon S, Dharmshale S, Chande C, Gohil A, Lilani S, Mohammad S, Joshi A, Chowdhary
A,Bharadwaj R. Drug resistance profiles of Mycobacterium tuberculosis isolates to first line
anti-tuberculosis drugs: A five years study. Lung India .2012; 29:227-31.
29. Ejaz M, Siddiqui AR, Rafiq Y, Malik F, Channa A, Mangi R, Habib F, Hasan R: Prevalence
of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups.
Trans R Soc Trop Med Hyg. 2010; 104 (8):511-17.
30. Javaid A, Hasan R, Zafar A, Ghafoor A, Pathan AJ, Rab A, Sadiq A, Akram CM, Burki I,
Shah K, Ansari M, Rizvi N, Khan SU, Awan SR, Syed ZA, Iqbal ZH,Shaheen Z, Rehman
N: Prevalence of primary multidrug resistance to anti-tuberculosis drugs in Pakistan. Int J
Tuberc Lung Dis. 2008; 12(3):326-31.
31. K. Wallengren, F, F. Scano,P. Nunn, B. Margot,S. Buthelezi, B. Williams, A. Pym, E. Y.
Samuel,F. Mirzayev, W. Nkhoma, L. Mvusi, and Y. Pillay: Resistance to TB drugs in
KwaZulu-Natal: causes and prospects for control. Pulmonary Medicine.2013; 1(13):34-38.
32. Ejilude Oluwaseun, Akinduti Paul Akinniyi, Oluwadun Afolabi: Primary Multi-Drug
Resistance Tuberculosis among HIV-Seropositive and HIV-Seronegative Patients in
Abeokuta, Southwestern Nigeria. Amer J ResCommu. 2013; 1(10):518-25.
33. Asmamaw D, Seyoum B, Makonnen E, etal: Primary drug resistance in newly diagnosed
smear positive tuberculosis patients in Addis Ababa, Ethiop Med J. 2008 Oct;46(4):367-74.
36
34. Meskel DW, Abate G, Lakew M, Goshu S, Aseffa A,Anti-tuberculosis drug resistance
among retreatment patients seen at St Peter Tuberculosis Specialized Hospital.Ethiop Med J.
2008 Jul; 46(3):219-25.
35. Agonafir M, Lemma E, Wolde-Meskel D, Goshu S, Santhanam A, Girmachew F, Demissie
S, Getahun M, Gebeyehu M, van SoolingenD: Phenotypic and genotypic analysis of
multidrug-resistant tuberculosis in Ethiopia.J Tuberc Lung Dis. 2010 Oct; 14(10):1259-65.
36. Law WS, Yew WW, Chiu Leung C, Kam KM, Tam CM, Chan CK, Leung CC: Risk factors
for multidrug-resistant tuberculosis in Hong Kong. Int J Tuberc Lung Dis. 2008; 12(9):65-
70.
37. Caminero, J. A: Multidrug-resistant tuberculosis: epidemiology, risk factors and case
finding. Int J TuberLung Dis, 2010;14(4):382-90.
38. M. Casal, M.Varquero, H.Rinder, E.Tortoli, J.Grosset, and Rüsch-Gerdes: A Case-Control
Study for Multidrug-Resistant Tuberculosis and Risk Factors in Four European Countries.
Micro Drug Res. 2005; 11(1):11-25.
39. Suarez Garcia &A. Rodriguez-Blanco & J. L. Vidal-Pérez & M. A. García-Viejo & M. J.
Jaras-Hernández &O. López& A. Noguerado-Asensio: Risk factors  for multidrug-resistant
tuberculosis in a tuberculosis unit in Madrid. EurJ ClinMicrobiol Infect Dis (2009) 28:325–
30.
40. Balaji V, Daley P, Anand AA, Sudarsanam T, Michael JS, et al. Risk Factors for MDR and
XDR-TB in a Tertiary Referral Hospital in India. PLoS ONE. 2010; 5(3): 9527.
41. Espinal M, A. Laserson, K Camacho, M.Fusheng, Z. Kim S. etal: Determinants of drug-
resistant tuberculosis: analysis of 11 countries. Int J TuberLung Dis. 2010;5(10):887-93.
42. Philip M Ricks, FaraiMavhunga, SurbhiModi, RosaliaIndongo, Abbas Zezai, Lauren. A
Lambert, Nick DeLuca, Jamie S Krashin, Allyn K Nakashima and Timothy H Holtz:
Characteristics of multidrug-resistant tuberculosis in Namibia. BMC Infect Dis.2012;
12:385.
43. Olusoji Daniel, Eltayeb Osman: Prevalence and risk factors associated with drug resistant
TB in South West, Nigeria. Asian PaciJ Trop Med.2011; 4(2):148-51.
44. Sanchez-Padilla E, Dlamini T, Ascorra A, Rüsch-Gerdes S, Tefera ZD, Calain P, etal. High
prevalence of multidrug-resistant tuberculosis, Swaziland, Emerg Infect. 2012; 18 (1):234-
38.
37
45. Flora MS, Amin MN, Karim MR, Afroz S, Islam S, Alam A, Hossain M: Risk factors of
multi-drug-resistant tuberculosis in Bangladeshi population: a case control study.
Bangladesh Med Res Counc Bull. 2013; 39(1):34-41.
46. Gemeda Abebe, Ketema Abdissa, Alemseged Abdissa, Ludwig Apers, Mulualem
Agonafir,Bouke C de-Jong and Robert Colebunders: Relatively low primary drug resistant
tuberculosis in southwestern EthiopiaBMC Research Notes 2012; 5(225):1756-59.
47. Selamawit Hirpa, Girmay Medhin, Belaineh Girma, Muluken Melese,Alemayehu Mekonen,
Pedro Suarez, Gobena Ameni: Determinants of multidrug-resistant tuberculosisin patients
who underwent first-line treatment in Addis Ababa: a case control studyBMC Public Health
2013; 13(782):1471-78.
38
13. ANNEXES
ANNEX 1. Questionnaire (English Version)
Prevalence of MDR-TB and associated Risk Factors inWest Armachiho and Metema
woredas of North Gondar Zone, North West Ethiopia Questionnaire
Case Number: _____________Lab.No________
Diagnostic center__________Date of sputum collection: ______________Time of
collection___________
A. Socio-demographic data of the patient
1.Age: _________ (Exact number)
2. Sex:
1. Male                                 2.Female
3. Resident
1.Urban 2. Rural
4. Occupation:
1. Farmer 2. House wife
3. Government employee 4. Merchant
5. Daily laborer6. Driver
7. Other specify______
5. Income/ month:
a. < 500 birr
b. 500 birr - 999 birr
c. > 1000 birr
d. No means of income
e. Other specify
6. Religion:
1. Christian
2. Muslim
3. Other (specify) _______________
7. Do you fast on regular basis?
1. Yes
2. No
39
8. Ethnicity:
1. Amhara
2. Tigre
3. Other (specify)______
9. Educational Status:
1. Illiterate
2. Primary School
3. Secondary School
4. Diploma
5. Degree and above
10. Marital Status:
1. Married
2. Un married
3. Widowed
4. Divorced
B. Risk Factors
B1. Do you have a history of cigarette Smoking?
1. Yes
2. No
B2.Are you Smoking now?
1. Yes
2. No
B3. Do you have history of contact to a person with chronic cough?
1. Yes
2. No
B4.Do you have diabetes?
1. Yes
2. No
B5. Is the patient previously treated for TB?
1. Yes
40
2. No
B6.If the answer in B5 is yes,
B6 .1.How long have you been treated for TB before? (in months)--------------------
B6.2.How frequent have you been treated for TB before?
1. Once
2. Twice
3. Three times
B7. Outcome of the last treatment according to the patient:-
1. Cured/ Treatment completed
2. Failed
3. Defaulted
4. Unknown
B8. History of prison stay
1.Yes
2.No
B9. If the answer to B8. Is yes for how long(weeks)______________
B.10.How many rooms do you have?_________________
B.11.Total number of family members? _____________
B.12. How many rooms in this household are used for sleeping? ______________
B.13.How many windows in the household are there? ______________________
B.14.On average how many people are sleeping in one bedroom in your household?
__________________________
B.15.BCG vaccination status
B.15.1 BCG scar: 1.Present            2.Absent
B.15.2 BCG vaccination card: 1.Present            2.Absent
B.16 HIV Status                          1.Positive 2.Negative
B.17.History of Illegal drug use 1.Yes 2.No
Name of data
collector___________________________Signature___________Date_____________
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ANNEX2.Amharic Questionnaire
በሰሜንጎንደርዞንበምዕራብአርማጭሆእናመተማወረዳዎቸመድሀኒትየተለማመደቲቢእናየችግሩተያያዥአጋላጭመንስኤዎችለማ
ጥናትየተዘጋጀመጠይቅ
1. የግለሰቡ ማህበራዊ ና ሥነ-ህዝባዊ መረጃዎቸን ለማጥናት በተመለከተ
ተ.ቁ ጥያቄዎች አማራጭመልሶች ኮድ ይለፍ
1 ዕድሜዎ ስንትነዉ? …………………. ዓመት
2 ፆታ 1.ወንድ
2.ሴት
3 የመኖሪያቦታዎየትነዉ? 1.ከተማ
2.ገጠር
4 መተዳደሪያዎምንድንነዉ? 1. ገበሬ
2. የቤትእመቤት
3. ተማሪ
4. ነጋዴ
5. የመንግስትሰራተኛ
6. ሌላካለይገለጽ ………………………………………
5 የወርገቢዎምንያህልነው; 1. ከ500 ብርበታች
2. ከ500 እስከ 999 ብር
3. ከ1000 ብርበላይ
4. ምንምየገቢምንጭየሌለው
5.
ሌላካለይጠቀስ……………………………………………
6 የምንሀይማኖትተከታይነዎት; 1. ክርስቲያን
2. ሙስሊም
3. ሌላካለይገለጽ---------------
7 አዘውትረውይፆማሉ; 1. አዎ 2. አይደለም
8 የምንብሄርአባልነዎት; 1. አማራ 2.ትግሬ 3.ሌላ ከሆነይጠቀስ
9 የትምህርትደረጃ 1. ያልተማረ
2. 1ኛ ደረጃያጠናቀቀ
3. 10ኛ /12ኛ/ ያጠናቀቀ
4. ዲፕሎማናከዚያበላይ
10 የጋብቻሁኔታዎምንድንነው? 1. ያገባ
2. ያላገባ
3. የሞተበት
4. የተፋቱ
2.የችግሩ ተያያዥአጋላጭመንስኤዎች
2.1 ከአሁንበፊትሲጋራያጨሱነበር; 1. አዎ2. አላጨስም
2.2 አሁንስያጨሳሉ? 1. አዎ2. አላጨስም
2.3 ለብዙጊዜሳልከሚስልሰውጋርግንኙነትነበረ 1. አዎ2. የለም
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ዎት?
2.4 የስኳርህመምተኛነዎት? 1. አዎን 2. አይደለሁም
2.5 ከአሁንበፊትበቲቢበሽታታክመዉያዉቃሉ? 1. አዎ 2. አይደለም
2.6.1 ለጥያቄቁጥር 2.5መልስዎ “አዎ”
ከሆነለምንያህልጊዜተከታትለዋል? (በ
ወራት)
--------------------
2.6.2 ለጥያቄቁጥር 2.5 መልስዎ “አዎ” ከሆነ
ለምንያህልጊዜ ደጋግመዉ ተከታትለዋል?
1. አንድጊዜ
2.ሁለትጊዜ
3.ከሁለትጊዜበላይ
2.7
በመጨረሻውየህክምናክትትልጊዜየበሽተኛ
ውውጤትምንነበር?
1. የዳነወይምህክምናየጨረሰ
2. ህክምናዉ የ መከነ
3. ህክምናዉየተቋረጠ
4. ያልታወቀ
2.8
የህግታራሚሁነዉማረሚያቤትገብተዉያዉ
ቃሉ? 1. አዎ2. አይደለም
2.9 ለጥያቄቁጥር 2.8 መልስዎ “አዎ”
ከሆነለምንያህልጊዜ ( በ ሳምንታት )
2.9 መኖሪያቤትዎ ምንያህል ክፍሎቸ አሉት?
2.10 የቤተሰብዎአባላት ምንያህል ናቸዉ?
2.11 በመኖሪያቤትዎ ምንያህል
ክፍሎችለመኝታአገልግሎትይዉላሉ?
2.12 በመኖሪያቤትዎ ምንያህል መስኮቶችአሉ?
2.13 በመኖሪያቤትዎበ አንድአልጋምንያህል
ሰዎችይተኛሉ?
2.14 ለቲቢበሺታ መከላክያ ክትባትሁኔተ
2.14.1 ለቲቢበሺታ መከላክያ ክትባት
መዉሰዳቸዉን የሚያረጋግጥጠባሳምልክት? 1. አዎ 2. የለም
2.14.2 ለቲቢበሺታ መከላክያ ክትባት
መዉሰዳቸዉን የሚያረጋግጥካርድ? 1. አዎ 2. የለም
2.15 ኤችአይቪውጤት 1.ፖዘቲቭ2.ኒጋቲቭ
2.16 ከ ጤና ተቁዋም ዉጭ የቲቢ መድሃኒት
ወስደዉያዉቃሉ?
1. አዎ2. አላዉቅም
ይህንንመረጃክቡርጊዜዎን ሰዉተዉ ስለሰጡንበጣምእናመሰግናለን!!
የጠያቂውስም……………………………………………የተቆጣጣሪውስም…………………………………………………………
ቀን …………………………………………….. ቀን …………………………………………………
ፊርማ ………………………………………… ፊርማ …………………………………………
ANNEX 3: Information and Consent form
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Title of the Research Project: Prevalence of MDR-TB and associated Risk Factors in West
Armachiho and Metema Woredas of North Gondar, North West Ethiopia
Name of Investigator: Feleke Mekonnen Demeke (BSc, MSc candidate)
Name of the Organization: University of Gondar, School of Biomedical and Laboratory
science, Department of Medical Microbiology
Introduction
You are invited to participate as study subject in a research conducted by MSc candidate, from
University of Gondar. Your participation is voluntarily. The research teams include one principal
investigator, sample collectors, three advisors from university of Gondar. Please take as much
time as you need to read or listen the information sheet.
Purpose of the Research Project
We are asking you to take part in this study because we are trying to learn more about the
prevalence of MDR-TB in West Armachiho and Metema woredas and risk factors associated for
the exposure to this catastrophic disease. This research is designed for effective prevention and
control measure.
Procedure
In order to perform the indicated study at Gondar university hospital you are invited to take part
in this project. If you are willing to participate, you need to understand the purpose of the study
and give your consent. The required sputum sample will be collected by Laboratory personnel
who are currently working in the health center. Then, you are requested to give your consent to
the sample collector.
Potential Risks and Discomforts
There are no anticipated risks to your participation. You are simply requested to take some time
and give productive sputum sample. During collection of sputum you should collect sputum in
places where there is well ventilatilation and no other persons at time of collection not to
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transmit the disease to others but personally there is no any procedure or discomfort that will
affect your health.
Potential benefits to subjects and/or to the society
Based on the diagnosis result you will be treated accordingly. On the other hand, the result of the
study will be beneficial to design effective prevention and control measure for MDR-TB. Hence,
you are indirectly benefiting other patients and the society in this respect.
Compensation for participation
You will not receive any payment for your participation in this research study.
Confidentiality
There is no sensitive issue that you will be asked related with your social desirability but any
information that is obtained in connection with this study and that can be identified with you will
remain confidential. The information collected about you will be coded using numbers.
Participation and withdrawal
You can choose whether to be a part of this study or not. You may withdrawal at any time
without consequences of any kind. You may also refuse to give any sample.
Person to contact
If you have any question you can contact any of the following (Investigator and Advisors) and
you may ask at any time you want.
FELEKE MEKONNEN (BSc),Cell phone: +251- 09 18 701291/ 0913 863665
Dr. BELAY TESSEMA (PhD.), Cell phone: +251- 09 19306918
Dr. FELEKE MOGES (PhD.), Cell phone: +251- 09 18 778160
Mr. ASCHALEW GELAW (MSc.), Cell phone: +251- 09 18 711787
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Patient consent form
I the undersigned patient with smear positive Tuberculosis case have been well informed about
the objective of the study entitled “Prevalence of Multi Drug Resistance Tuberculosis and
Associated Risk Factors in West Armachiho and Metema Woredas of North Gondar, North West
Ethiopia”. I am also told that all information obtained at any course of the study is to be kept
confidential. Moreover, i have also been well informed of my right to keep hold of, decline to
cooperate and drop out of the study if i want and none of my actions will have any bearing at all
on my overall health care and hospital access.
Therefore, with full understanding of the situations i agree to give the entire necessary
information and sputum samples for laboratory analysis.
Name_______________________________Signature______________Date_____________
For families or attendants of patients unable to respond
I______________________________________ parent/guardian/attendant, after being fully
Informed about the purpose of this study, hereby give my consent on the patient’s participation
in this study. I understand that my child free to withdraw at any time without penalty or loss of
benefits.
Signature____________________________Date_____________
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ANNEX4.የጥናቱ ማብራራያ / information sheet/
1. የጥናቱርዕስ
መድሃኒት የተለማመደቲቢበሽታስርጭትእናተያያዠለከፋአደጋሊያጋልጡየሚችሉመንሰስኤምክንያቶቸንማወቅ
2. ጥናቱንየሚያካሔውሰውፈለቀመኮንንደመቀ
3. የትምህርትደረጃየሁለተኛዲግሪተማሪ/Msc student /
4. የመስሪያቤቱስም
የጎንደርዩኒቨርስቲህክምናፋኩሊቲየባዬሚዲካልእናላቦራቶሪሳይንስትምህርትቤትየማይክሮባዬሎጂትምህርትክፍል
5. ለጥናቱተሳታፊዎችየተሰጠማብራሪያ
5.1. መግቢያ
በመጀመሪያእርዕስዎበዚህጥናትውስጥተሳታፊእንዲሆኑሲጠየቁተሳታፊየሚሆኑትፈቃደኛከሆኑብቻነው፡፡ይህንንጥናትየሚያካ
ሒዱትሰዎችአንድዋ ና ተመራማሪ ሶስት የጥናቱአማካሪዎችእናናሙናሰብሳቢዎቸንያካተተነው፡፡
5.2. የጥናቱዓላማ
መድሃኒት የተለማመደቲቢበሽታስርጭትእናተያያዠለከፋአደጋሊያጋልጡየሚችሉመንሰስኤምክንያቶቸንማወቅ፡፡
5.3. ለጥናቱየሚያስፈልግናሙናአወሳሰድ
ይህንጥናትለማካሔድየዕርሱንፈቃደኛነትዎንማግኘትአስፈላጊነው፡፡የጥናቱንአላማናጥቅምበሚገባተረድተውለመሳተፍፍላጎትካ
ለውት
ሀ. ናሙናለሚወስደውሰውወይምዋናተመራማሪለሚጠይቅዎትጥያቄተገቢውንመልስይሰጣሉ፡፡
ለ. ለምርምርየሚያስፈልገውንናሙናይሰጣሉ፡፡
5.4. ጥናቱየሚያስገኘውጥቅም
የምርምሩውጤት መድሃኒት የተለማመደቲቢበሽታስርጭትለመግታትናለመቆጣጠርይረዳል፡፡
5.5. በዚህጥናትውስጥበመሳተፍሊከሰቱየሚችሉስጋቶችናየምቾትመጓደሎች
ለጥናቱበሚወስደውናሙናምክንያትሊከሰትብዎየሚችልየተለየችግርእናየሚያሰጋምንምአይነትነገርየለም
5.6. ምስጥርአጠባባቅ
ለዚህጥናትከርስዎየምንወስደዉመረጃወይምናሙናየርስዎንማህበራዊተቀባይነትስጋትላይእይጥልም፡፡ይህቢሆንከርስዎየተገኘማ
ንኛውምመረጃበሚስጥርእንደሚያዝለማረጋገጥእወዳለሁ፡፡
5.7. በጥናቱየሚሳተፉወይእራስንየማግለልመብት
በጥናቱውስጥመግባትባለመፈልግዎተሳታፊሆነውማቋረጥሲፈልጉበጤናነክእንክብካቤላይምንምአይነትተጽኖአይደረግም፡፡
እንዲሁምተሳታፊበመሆንዎየተለየእንክብካቤአያገኙም፡፡
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ተጨማሪመረጃከፈለጉዋናውንተመራማሪወይምአማካሪዎችማነጋገርይችላሉ፡፡
የተመራማሪዉየሞባይል ስልክቁጥር 0918 70 12 91/0918863665
የአማካሪዎችስልክቁጥር
ዶ/ር በላይ ተሰማ የሞባይል ስልክቁጥር+251- 09 19306918
ዶ/ር ፈለቀ ሞገስየሞባይል ስልክቁጥር+251- 09 18 778160
አቶ አስቻለዉ ገላዉ የሞባይል ስልክቁጥር+251- 09 18 711787
በምርምሩለመሳተፍየስምምነትመግለጫ
እኔከዚህበታችስሜየተጠቀሰውናየፈረምኩትየሳንባነቀርሳህመምተኛ “መድሃኒት የተለማመደቲቢበሽታ ስርጭት እናተያያዠ ለ
ከፋአደጋሊያጋልጡየሚችሉመንሰስኤምክንያቶቸንለማወቅ”
በጥናቱባልሳተፍምሆነአቋርጬብወጣከጤናተቋሙበማገኘውየህክምናአገልግሎትምንምአይነትችግርእንደማደርስብኝተነግሮኛ
ል፡፡በመሆኑምየአክታናሙናምሆነለምጠየቀዉመጠይቅመልስለመስጠትሙሉፈቃደኛመሆኔንእገልጻሁ፡፡
ስም------------------------------------------------------ፊርማ ----------------------------------------------------- ቀን፡ -----/-----/-----
ለሕፃናትና ሀሳባቸውን መግለፅ ለማይችሉ አዋቂዎች አስታማሚዎች
እኔ ____________________________________________ የበሽተኛው አስታማሚ ስሆን የዚህን ጥናት ዓላማ በውል በመገንዘብ
በሽተኛው በጥናቱ እንዲሳተፍ የምስማማ መሆኔን በፊርማዬ አረጋግጣለሁ፡፡
ፊርማ ----------------------------------------------------- ቀን፡ -----/-----/-----
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ANNEX 5: Principle and Procedure of LJ medium
Lowenstein–Jensen (LJ) drug-containing media were used for drug susceptibility testing of M.
tuberculosis according to the proportion method.
Equipment and materials
The equipment and materials needed were:
- Balance (sensitivity 0.01 g)
- Spoons or spatulas
- Weighing paper
- Autoclave
- Inspissator and racks to hold slopes in correct position
- pH meter
- Simple dispenser device – either an automatic pipetting aid or a mechanical pipetting aid
with thumb wheel or rubber teats
- Appropriate sterile glassware and sufficient sterile screw-capped tubes for media
dispensing
Note: Because of the risk of infection if glass tubes break, thick-walled, shock-resistant glass
tubes or vials were used.
Material for homogenization of egg mass (5-mm glass beads for manual shaking, a plate with
magnetic stirrer, or a sterile low-speed blender with sterile glass/stainless steel bowl).
Thick walled conical flask, 2500 ml, Bunsen burner, Forceps, Funnel with sterile gauze, for
filtration of homogenized egg preparation, Water-bath, Brown bottles, Vortex mixer
General equipment and glassware of a laboratory for media preparation
Small desicants, device for drug storage in dry conditions
Silica gel, Refrigerator
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Reagents and solutions
Drug-containing media
Drugs are added to the still-liquid LJ medium before inspissations. Final drug concentrations
were indicated in Table below.
Each test-tube were labelled with the following information:
 Date of preparation, name, and concentration of drug.
Final concentrations of drugs for quality control and for test strains
Test drugs Solvent Final mass concentration in
culture medium (mg/litre)
Designation Abbre Solvent Dilution For quality
control H37Rv
Critical
conc.
Isoniazid INH Sterile dw Sterile dw 0.025•0.05•0.10 0.2
Rifampicin RMPa DMSO dw 2.5•5.0•10.0 40.0
NB- forDrug susceptibility testing inproportion method - Drugs were stored indesiccators
according to the manufacturers’ instructions. The amount weighed were calculated according to
the activity (potency) declared by the manufacturer and the water content.
Preparation of Drugs for DST
A standard batch (1620 ml) of LJ basic culture medium wasPrepared according to the SOP
“Preparation of plain egg-based media”. If multiple growth controls were included in the DST
schema, the volume of this standard batch must be increased enlarged accordingly.
• Isoniazid (INH)
For dry and pure INH, the correction factor was 1.
Solution I: 10.0 mg INH dissolved in 50 ml sterile water (200 µg/ml)
Solution II: 2.5 ml Solution I, made up to 25 ml with sterile water (20 µg/ml)
Solution III: 5.0 ml Solution II, made up to 10 ml with sterile water (10 µg/ml)
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Stock solution I (200 µg/ml)aliquated into sterile cryovials and stored frozen at -20 °C.
Final drug concentration in media (µg/ml):
0. 2 µg/ml 0.1 µg/ml 0.05 µg/ml 0.025 µg/ml
Medium (ml) 198 19.8 19.8 19.8
Solution II (ml) 2 – – –
Solution III (ml) – 0.2 0.10 0.05a
Water (ml) – – 0.10 0.15a
Final volume (ml) 200 20 20 20
aGraduated glass pipettes or single-channel adjustable microlitre-pipettes with sterile tips
were used for accurate delivery.
• Rifampicin (RMP)
The correction factor was usually 1 for pure RMP or 1.03 for the sodium salt:
Solution I:
Factor 1: 40.0 mg RMP, dissolved in 10.0 ml DMSO (4000 µg/ml)
Factor 1.03: 41.2 mg RMP, dissolved in 10.0 ml sterile water (4000 µg/ml)
Solution II: 2.5 ml Solution I, made up to 10.0 ml with sterile water (1000 µg/ml)
Final concentration in drug media (µg/ml):
40 µg/ml 10 µg/ml 5 µg/ml 2.5 µg/ml
Media (ml) 198 19.8 19.8 19.8
Solution I (ml) 2 – – –
Solution II (ml) – 0.2 0.10 0.05a
Water (ml) – – 0.10 0.15a
Final volume (ml) 200 20 20 20
aGraduated glass pipettes or single-channel adjustable microlitre-pipettes with sterile tips
were used for accurate delivery.
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ANNEX 6: Principle and Procedure GeneXpert
The GeneXpert Dx System integrates and automates sample processing, nucleic acid
amplification, and detection of the target sequences in simple or complex samples using real-
time PCR and reverse transcriptase PCR. The system consists of an instrument, personal
computer, barcode scanner, and preloaded software for running tests on collected samples and
viewing theresults. The system requires the use of single-use disposable GeneXpert cartridges
that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained,
cross-contamination between samples is eliminated. Xpert MTB/RIF includes reagents for the
detection of tuberculosis and RIF’s resistance as well as a sample processing control (SPC) to
control for adequate processing of the target bacteria and to monitor the presence of inhibitor(s)
in the PCR reaction. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube
filling in the cartridge, probe integrity, and dye stability. The primers in the Xpert MTB/RIF
assay amplify a portion of the rpoB gene containing the 81 base pair “core” region. The probes
were able to differentiate between the conserved wild-type sequence and mutations in the core
region that were associated with RIF’s resistance.
Specimen Collection and Transport
 A minimum of 1 mL of sputum per specimen were Collected.
 Specimens were held at 2–8 °C prior to processing whenever possible. However, if
necessary the specimens’could notprocessed, specimens were stored at a maximum of 35
°C for 3 days and at 4 °C for days 4-10.
1. Thepatient’s were advised to Rinse mouth twice with water.
2. Thepatient’s were advised to unscrew the lid on the sputum collection container.
3. Thepatient’s were advised inhale deeply, cough vigorously, and expectorate the material into
the sterile screw-capped specimen collection container. Avoid spills or soiling the outside of the
container.
4. Secure the lid on the collection device.
5. Specimens were held at 2–8 °C whenever possible including during transport to the laboratory
if not they were stored at -4°C.
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Procedure for Sputum Sediments
Specimens with obvious food particles or other solid particulates were not accepted.
Volume Requirements—Sputum sediments prepared according to the method of Kent and
Kubica8 and re-suspended in 67mM Phosphate/H2O buffer) can be tested using Xpert
MTB/RIF. Once the resuspension was prepared for standard laboratory smear or culture tests, at
least 0.5 mL of resuspended sediment were ensured available to run Xpert MTB/RIF.
1. Each Xpert MTB/RIF cartridge were Labeled with the sample ID. (Labeling was written on
the sides of the cartridge or affix ID label.) The labels on the lid of the cartridge were not written
not obstruct the existing 2D barcode on the cartridge.
2. At least 0.5 ml of the total resuspension pellet was transferred to a conical, screw-capped tube
for the Xpert MTB/RIF using a sterile transfer pipette. Alternatively, the entire sample might
also be processed in the original tube.
3. Re-suspended sediments were storedat 2–8 °C if they were not immediately processed for
Xpert MTB/RIF.
4. 1.5 ml of Xpert MTB/RIF Sample Reagent (SR) to 0.5 mL of resuspended sediment sample
using a sterile transfer pipette was added and shaked vigorously 10 – 20 times. Note: One back-
and-forth movement was a single shake.
5. The specimens’ were incubated for 15 minutes at room temperature. At one point between 5
and 10 minutes of the incubation, again shaked the specimen vigorously 10–20 times. Samples
were liquefied with no visible clumps of sputum.
Procedure for Preparing the Cartridge
The test must be started within 30 minutes of adding the sample to the cartridge.
1. Using the sterile transfer pipette provided, the liquefied sample was aspirated into the transfer
pipette until the meniscus was above the minimum mark.
2. Then the cartridge lid opened. Samplewas transferredinto the open port of the Xpert MTB/RIF
cartridge.
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3. The cartridge lid was closed for each and inserted in to the machine for analysis. Remaining
liquefied sample was kept for up to 12 hours at 2–8 ºC should repeat testing be required. After
the cartilages was loaded into the GeneXpert Dx instrument and the test was started within 30
minutes of preparing the cartridge.
Quality Control
Each test includes a Sample processing control (SPC) and probe check (PCC).
Sample Processing Control (SPC): Ensures the sample was correctly processed. The SPC
contains non-infectious spores in the form of a dry spore cake that was included in each cartridge
to verify adequate processing of MTB. The SPC verifies that lysis of MTB has occurred if the
organisms were present and verified that specimen processing was adequate. Additionally, this
control detected specimen-associated inhibition of the real-time PCR assay. The SPC was
positive in a negative sample and could be negative or positive in a positive sample. The SPC
passedmeeting the validated acceptance criteria.  The test result will be “Invalid” if the SPC was
not detected in a negative test.
Probe Check Control (PCC): before the start of the PCR reaction, the GeneXpert Dx System
measures the fluorescence signal from the probes to monitor bead rehydration, reaction-tube
filling, probe integrity and dye stability. Probe Check was passed meeting the assigned
acceptance criteria.
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